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Abstract
In this essay, which is to be read in conjunction with papers [1-9] included as the Appendix to 
this thesis, I aim to present the necessary background on the biology o f Varicella-Zoster Virus 
(VZV), the clinical manifestations o f VZV, and an up-to-date picture o f the available knowledge 
on VZV latency. I situate the work done in Prof. P. G. E. Kennedy’s laboratoiy in the current 
literature and describe my contribution to that work. In the last chapter I put foiward a model o f 
latency that is consistent with many experimental findings and suggest some possible directions 
for future research.
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Summary
In this thesis essay, which is to be read in conjunction with papers [1-9] contained in the Ap­
pendix, I describe work conducted in Prof. P.G.E. Kennedy’s laboratory over the last eight years 
on the topic o f Varicella-zoster virus (VZV) latency in the nervous system.
In the papers that comprise the present thesis, I studied various aspects o f VZV latency in human 
PNS, a rat model and latent Simian Varicella Virus (SVV) in the PNS o f African green monkeys. 
In particular, I investigated questions o f latent vims localisation, viral gene expression during 
latency, and if VZV might be involved in Giant Cell Arteritis (GCA) o f humans. All these topics 
have given rise to controversies in the literature and the key aim of our research was to attempt 
to resolve them by using sophisticated and reliable molecular biological techniques.
Our first paper on the subject o f VZV latency [1] in which the polymerase chain reaction (PCR), 
in situ hybridisation (ISH) and in situ PCR amplification (ISPCR) were used on human trigem­
inal ganglia (TG), resolved a 10 year old controversy in the literature concerning the type of 
cells harbouring latent VZV. The results provided unambiguous evidence that latent VZV re­
sides predominantly in the nuclei o f neurons, occurring in 2-5%  o f neurons whereas it was 
found in only a vanishingly small fraction (less than 0 .1%) of non-neuronal satellite cells.
Our DRG studies [2] confirmed this finding and indicated that more than one region o f VZV 
genome was present. The co-localisation of 2 regions of the VZV genome in serial sections by 
(ISPCR) was shown and found both DNA and RNA in serial sections o f the same tissue.
Since the functions o f several genes expressed in latency may be known, this may help in un-
derstanding the mechanisms o f latency and could identify genes and proteins which could act 
as therapeutic viral targets, for example, for anti-sense therapies, RNA silencing or vaccine de­
velopment. This has been the second major direction o f the work. In association with J. E. 
Bell, a study of VZV gene expression in latently infected and explanted TG and DRG of pa­
tients using ISH to detect gene products was conducted [3]. It was indicated that expression o f 
genes 18, 21, 29, 62, and 63 in latently infected ganglia, with the proportion of HIV-positive 
patients expressing the genes being consistently higher as might be anticipated. Explanted gan­
glia (from HIV- negative patients only) expressed in addition genes 28 and 40, the differences 
in expression patterns between latently infected and explanted ganglia presumably reflecting 
virus reactivation, thus indicating that what is referred to as ‘latency’ is probably latency and 
not low-level persistent lytic activity. The latter cannot, however, be completely excluded at the 
present time.
To analyse further the processes involved in latency establishment, the mechanisms controlling 
the activity o f gene 62 product, IE62 were investigated [4]. It is known that in latency this gene 
product is predominantly located in the cytoplasm, which may be the result o f its phosphoryla­
tion by gene 6 6  product, the protein kinase 6 6 -pk. Hence it is important to identify VZV gene 6 6  
expression during latency. The hypothesis proved to be correct in that transcripts for VZV gene 
6 6  were indeed detected in latently infected TG by RT-dependent nested PCR and ISH, while 
the 6 6 -pk itself was detected by immunohistochemistry. In addition, the presence of proteins 
coded for by the VZV genes 21, 29, 62 and 63 has been confirmed by immunohistochemistry 
in human tissues shown to contain latent VZV [5].
VZV and other viruses have been implicated as contributing factors in many diseases, and 
screening tissue from patients with various pathological conditions for the presence of viruses 
is an important step in elucidating potential pathogenetic mechanisms. The presence of VZV 
genome in temporal artery biopsies o f patients with Giant Cell Arteritis (GCA) was investigated. 
Viral involvement in GCA is plausible due to the presence in inflammatory cell infiltrates o f 
multinucleated giant cells, which often occur in viral infections, including those caused by VZV. 
Studies conducted previously have been contradictory. It was found, using ISH and ISPCR, that
7
there was no evidence o f the presence o f VZV in arteries o f GCA patients [6 ]. This strongly 
indicates non-involvement o f VZV in the development o f GCA.
A parallel study on DRG in a rat model of VZV latency was conducted [7]. The predominantly 
neuronal location o f latent VZV DNA was confirmed, an important result in animal model val­
idation. In addition, using ISH, it was confirmed that genes 21, 62 and 63 were most frequently 
expressed which is similar to human latency. However, viral transcripts were found in both a 
large number o f non-neuronal cells in contrast with the predominantly neuronal localisation in 
humans. These studies have been extended using mutants in order to determine the importance 
o f specific viral genes in establishing a latent infection [8 ]. Using VZV gene 14 and 67 deletion 
mutants, viral DNA was detected and genes 21, 29, 62 and 63 were still expressed. Therefore 
it was concluded that gene 14 and 67 products, glycoproteins gC and gl, are not necessary for 
the establishment o f latency. It was also confirmed that the model represents true latency as 
peripheral tissues did not contain VZV DNA.
The animal model studies were extended to the SVV model in African green monkeys. In these 
monkeys SVV causes a varicella-like illness which has many similarities to its human counter­
part. In naturally infected monkeys in which a latent SVV infection had been established, we 
used ISH and ISPCR to show that latent SVV resides in ganglionic neurons as demonstrated by 
the presence o f DNA for SVV genes 63 and 21 [9]. In contrast to human ganglionic latency we 
found that SVV DNA was localised in the neuronal cytoplasm rather than the nucleus, although 
the reason for this difference is as yet imclear. This primate model is a promising development 
in the search for alternatives to working on human tissue.
In summary, a variety o f molecular techniques have been used to make a number of important 
contributions to the difficult issues o f  latent ganglionic VZV nucleic acid localisation and latent 
viral gene expression in humans and animal models. We have also shown that this approach can 
be used in assessing possible VZV involvement in human CNS disease.
Chapter 1
Introduction
Varicella Zoster Vims (VZV) is an alphahei-pesvims that causes a primary infection known as 
varicella (chickenpox). The vims then becomes latent in the cranial, autonomic, dorsal root 
(DRG) and trigeminal (TG) ganglia and, after a variable period, it can be reactivated in later 
life, causing herpes zoster (shingles) which is a painful vesicular eruption usually limited to 
the distribution o f one or more dermatomes. The most important complication o f zoster is 
post-heipetic nem algia (PHN), but VZV infections are also associated with a wide variety of 
serious neurological complications such as encephalitis, myelitis and vasculitis, especially in 
immunosuppressed individuals [42]. It has therefore been the object o f much research work in 
the last two decades. Since VZV infections and their complications occur at the later stages 
of life, demographic changes will make understanding its biology and pathology even more 
important in the years to come; in fact, it has been dubbed the “re-emerging infection o f the 
early XXIst centuiy” [61].
The longterm goal o f this research is to devise more effective therapies for, VZV reactivation in 
later life. A pre-requisite for this is to gain a full understanding o f all aspects o f VZV latency. 
Latency may be defined as a dormant state of the virus characterised by the absence of 
isolatable infectious virus, with limited transcription but one where the virus retains the 
capacity to be reactivated.
The following are key issues in VZV latency;
1. What cell types harbour latent VZV?
2. How is latency established and maintained? In particular, what genes are being tian- 
scribed and what proteins expressed during latency?
3. W hat signals trigger reactivation?
Answering these questions, which apply equally to HSV-I, is much harder for VZV, since VZV 
is cell-associated and is difficult to grow to high titre in culture. In addition, VZV replicates 
only in human and primate cells. Moreover, there is no universally accepted animal model o f 
VZV latency, since all the available ones, such as the Liège group rat model used in [7, 8 ] do 
not allow reactivation (though there is an in vitro model using guinea pig enteric neurons that 
apparently does [22]). These factors explain why our knowledge o f VZV latency has lagged 
behind that o f HSV.
Conclusively answering the questions above could have significant implications for developing 
novel therapeutic strategies. For example, a highly restricted gene expression pattern in VZV 
latency raises the possibility o f using anti-sense oligonucleotides or RNA silencing to block 
the function o f these expressed viral genes. The demonstration o f specific and limited protein 
expression during latency might also facilitate the development o f passive immunisation or non- 
live vaccines to block viral functions in the immunocompromised individual, and potentially 
reduce or prevent the development o f PHN (post-herpetic neuralgia), especially in the elderly 
population. Such vaccines would provide an alternative to the currently live attenuated vaccines.
Below I concentrate on questions 1 and 2, since answering them has been the basis of the 
research programme in Prof. P. G. E. Kennedy’s laboratory in the last eight years. Some remarks 
on question 3 are also contained in Chapter 2.
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Chapter 2
VZV biology
This chapter contains many important aspects o f VZV biology that are relevant to the latency 
studies I have performed in Professor Kennedy’s laboratory.
2.1 Introduction to VZV
VZV belongs to the subfamily Alphaherpesviridae o f the family Herpesviridae of double 
stranded DNA viruses. Herpesvimses are characterised by an icosahedral capsid o f diameter 
o f about 125 mn with 162 capsomer spikes embedded in a tegument, an amorphous proteina- 
ceous matrix. The virion is enveloped in a lipid membrane containing external glycoproteins; 
the overall diameter is about 215 nm [24].
One might assume that VZV is closely related to other alphaherpesviruses, such as HSV-1. This 
assertion is not always warranted and attempts to predict VZV gene product fimctions from the 
functions o f homologous HSV-1 proteins may be problematic. In the modern classification, 
VZV belongs (together with the really closely related simian varicella virus (SVV) and the 
Equine HVs 1 and 4) to the a2  group, while HSV-1 belongs to the a l  group. In common 
with gammaherpesvimses, VZV genome is partially expressed in latency. Differences between
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HSV-1 and VZV are noticeable already on the gross genomic level: VZV has a simpler type D 
genome (see below for description) while HSV-1 has a more complex type E genome typical o f 
a l  viruses [69]. The genome of HSV is larger than that of VZV (153Kb as opposed to 125Kb) 
and codes for more proteins (at least 74 for HSV as opposed to about 70 for VZV). The most 
revealing fact about these vimses is contained in Figure 17.2 B o f [69], from which it becomes 
clear that the branching o f  the phylogenetic tree that gave rise to the a l  and a2  groups occurred 
about 70 million years ago. This means that the two families o f vimses evolved their strategies 
of confronting the host’s (evolving) immune system independently. Therefore assuming that 
the two vimses should have arrived at the same solutions is not necessarily warranted.
In their illuminating discussion o f the evolution o f herpesviruses, M cGeogh and Davison sug­
gest a core 43 genes common to all these viruses and write (the italics are mine);
. . .  most o f the core gene complement of herpesviruses is concerned with specify­
ing the icosahedral capsid structure, with synthesizing and packaging progeny DNA 
and with cell entry mechanisms, while genes supplying all well-characterised con­
trolfunctions and also those fo r  virus tegument and surface components are specific 
to subfamilies or to lineages within subfamilies.
This point will be enlarged on in Chapter 6 .
2.2 VZV genome organisation
The VZV genome is a linear double-stranded DNA molecule containing about 125 Kbp. It 
comprises a unique long region [/%,, o f about 105 Kbp, flanked by inverted repeat regions, 
terminal repeat long region (TRL) and internal repeat (IRE) region; these are very short, about 
8 8  bp. The rest o f  the genome consists o f the unique short region, 5.2 Kbp long, flanked by 
terminal repeat short (TRS) and inverted repeat short (1RS) regions, each about 7.4 Kbp long. 
The orientations are independent, so the VZV genome exists in 4 isomeric forms, two of which
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predominate [24].
Though sequencing shows many minor amino acid differences, due to single nucleotide poly­
morphisms, between isolates o f VZV [24, 105] (e.g. comparisons o f VZV wild strain with the 
Oka vaccine strain show 15 differences in ORF62 alone), only a few distinct serotypes o f VZV 
are known, such as the VZV-MSP vims (a gE mutant). It is thought that this is a distinctive 
VZV population that emerged about 50 years ago [103].
The following picture o f the genome arises from recent studies (reviewed in [24, 29]): there 
are at least 70 unique VZV genes. ORFs 62, 63 and 64 are repeated (as ORFs 71, 70 and 69, 
respectively), but there are in addition VZV gene 33.5, 3’-coterminal with ORF 33, and VZV 
gene 9A, which maps inside ORF 8 . Finally, there is a gene ORF(S/L) which is spliced in the 
31 non-coding region. Eleven genes are thought to have overlapping reading frames. ORF42 
and ORF45 are probably spliced segments of the same gene.
There are six genes (ORFs 1,2, 13, 32, 57 and S/L) that have no homologs in the HSV genome. 
There is one gene, ORF 13 which in fact has no homologs in the alphaherpesvims family at all, 
but has a homolog among the gammaherpesvimses such as the Kaposi sarcoma vims.
The VZV genome is extremely stable but small numbers of single nucleotide polymorphisms 
can be used to distinguish tliree main genotypes; genotype A is common to Africa, Asia and 
the Far East, genotype C is the most common variant in The United Kingdom, and genotypes B 
and C in the United States and continental Europe [18].
2.3 Viral proteins
Throughout the years, a great deal o f information has been collected concerning VZV gene 
products. There are a number of ways o f organizing this data: by stage in the viral replication 
cycle in which they are synthesised (that is, immediate early (IE), early (E) and late (L); see 
below); by homology to HSV proteins (a practice can be somewhat misleading for reasons 
explained above); and by function. In this essay it was chosen to group VZV proteins by
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function, an approach also followed in [24]. The information contained in [24, 92] is used in 
this section and supplemented with newer findings. Below the standard notation ORFAp for 
the protein coded by 0RF2C is used; for immediate early proteins in this thesis the notation 
IE% is used, since this is the norm in the literature. Thus ORF62p and IE62 refer to the same 
protein.
2.3.1 Transactivators
This group o f VZV gene products includes mainly IE proteins, which are essential for the 
initiation o f the viral replication cycle; some of them, as explained below, are transported with 
the nucleocapsid into the nucleus o f the target cell. This group includes 0R F4p, ORF 1 Op, 
0R F61p, ORF62p and ORF63p. According to [92], all o f these apart from ORF 1 Op are IE 
proteins, while ORF 1 Op is a L protein with ORF62 transactivational activity. Since ORF62 and 
0RF71 are the same, as are ORF63 and ORF70, one might refer to ORF63p as ORF70p (or to 
IE63 as IE70), but again, the standard notation is used. For details o f transactivation activity of 
these proteins, the reader should consult Table 2 o f [92], noting the very complex concentration- 
dependent interactions among these proteins and their activation/repression activity on E and L 
genes. Here 0R F4p, ORF62p and ORF63p are concentrated on, as these are expressed in 
latency.
ORF4p is a 55-kD (452 amino acids) abundant tegument protein. Its localisation is mainly 
cytoplasmic but is influenced by ORF62p, which can cause its transport to the nucleus. It has 
been shown to transactivate promoters of IE, E, and L genes (by itself and in synergy with 
ORF62p) [35].
ORF62p is a 170-kD (1310 amino acids) abundant tegument protein. (Its molecular weight 
invites a comment. It is actually about 140-kD, but the protein is subject to a significant amount 
o f post-translational modification such as phosphorylation by cellular and viral kinases.) During 
the viral replication cycle, it resides in the nucleus; its localisation at latency is cytoplasmic 
and influenced by ORF6 6 p, a fact which is noted in Chapter 4 and in our paper [4]. This
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protein influences intracellular localisation o f other IE gene products, up- and down-regulates 
transcription o f other transactivators, interacts with them in an intricate manner and is known to 
interact with a number o f cellular factors, in particular with Spl and USE. Interaction with Spl 
is implicated in the regulation o f expression o f gE and gl, while USE influences expression of 
ORF28 and ORF29 [91].
ORF63p is a 45-kD tegument protein. It is found both in the nucleus and in the cytoplasm 
o f infected cells [36]. The only transactivational activity demonstrated for it is repression of 
ORF62 expression in tandem with 0RF4p.
Another protein that belongs in this section is ORF29p, an early gene product, which is the 
major DNA binding protein, a 130-kD protein localised in the nucleus o f  infected cells; it binds 
to single-stranded DNA and is known to modulate late gene promoter activity. It is expressed 
in latency.
2.3.2 Enzymes
These are mostly E gene products. Quite a number o f them are “luxury” gene products and are 
non-essential for replication and/or latency establishment. These include 0R F6p, a DNA he- 
licase component; ORF8 p, a dioxyuridine triphosphatase; 0R F13p, a thymidylate synthetase; 
0RF16p, a unit o f DNA polymerase; 0R F18p and 0RF19p, two components o f a ribonu­
cleotide reductase; ORF28p, a DNA polymerase; ORF33p, a pro tease; ORF33.5 encodes the 
virion assembly protein processed by ORF33p; ORF36p, a thymidine kinase; ORF47p, a pro­
tein kinase, implicated in T cell tropism [10]; ORF48p, a deoxyribonuclease, very important 
for viral DNA replication; ORFSlp, an origin-binding protein; ORF52p and ORF55p, compo­
nents o f a DNA helicase/primase complex; ORF59p, a uracil-DNA glycosylase, and another 
important protein kinase, ORF6 6 p, which has been implicated in ORF62p phosphorylation and 
cellular localisation and in skin tropism.
Since ORFs 18, 19 and ORFs 52 and 53 code for subunits o f enzymatic complexes that have
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no independent function separately, it would make sense always to look for expression o f both 
ORFs 18 and 19 at the same time, as it would provide a valuable quality control mechanism for 
molecular biology procedures.
It may be o f interest to speculate why VZV would need a ribonucleotide reductase. The expla­
nation provided in [69] is that genes encoding DNA replication as well as nucleotide generating 
enzymes have been captured from host genomes and proved usefiil in a host, such as terminally 
differentiated neurons, that need de novo synthesis of nucleotides.
2.3.3 Glycoproteins
There are 8  glycoproteins: ORF5 codes for gK; ORF 14 codes for gC, a glycoprotein involved 
in skin-specific vims/cell binding; ORF31 codes for gB, o f major importance in non-cell type 
specific virus/target cell binding; ORF37 codes for gH, important in cell binding (often in con­
junction with gL) and a major fusogen, responsible for syncytium formation; ORF50 codes for 
gM; ORF60 codes for gL, needed for gH expression; it also serves as a gH chaperone in the 
endoplasmic reticulum. ORF67 codes for gl, and finally ORF6 8  codes for gE; these two glyco­
proteins combine to foim  the viral Fc receptor. All the genes in this subsection are late genes. 
A detailed description o f the biochemistry o f the above glycoproteins is contained in [24].
2.3.4 Other proteins
Apart from capsid proteins, such as ORF40p and ORF21p, there are a number o f VZV gene 
products with unclear function. Only a selected few are mentioned here. The HSV homolog 
of ORF 17 is UL41, which codes for the host shut-off protein, an activity that has not been 
demonstrated in VZV. Recently, in [94] the authors characterised 0R F2p, a membrane phos- 
phoprotein. Finally ORF(S/L)p is a 21-kDa protein expressed during lytic growth; this protein 
is apparently involved in controlling viral cell adhesion properties [29].
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2.4 The VZV replication cycle
Like HSV, the replication cycle o f  VZV can be divided into three phases, virus adsorption and 
entry, viral gene transcription, and viral assembly and exit.
2.4.1 Absorption and entry
As in the case o f HSV, attachment o f the VZV virion to a target cell requires a concerted 
action o f its glycoproteins. Since heparin is Imown to inhibit absorption, it is likely that VZV 
attaches to heparan sulphate proteoglycans (HSPGs). The binding o f VZV to heparin is direct 
and it is conjectured that the gB viral glycoprotein mediates this process. It is also thought 
that the process o f attachment proceeds in two stages, the first, described above, being cell- 
type independent, with the result being the stabilisation o f the virion on the cell surface which 
enables tighter, cell-specific binding to occur. It is plausible that the gC-mediated VZV skin 
tropism described in [79] is realised through the second, cell-specific binding step. There are 
also indications o f gH and gH:gL complex involvement, and o f putative sites o f the secondary 
attachment being mannose-6 -phosphate receptors on the cell surface. This is supported by the 
recent work o f Chen et al. [23], who found that human cell lines deficient in cation-independent 
mannose-6 -phosphate receptor resisted infection by cell-free VZV. Sadzot-Delvaux et n/.[92] 
state:
Obviously, eight glycoproteins is much more than needed for the above-described 
phenomenon. The additional glycoproteins could play identical roles as described 
above when the virus enters various cell types such as epithelial cells, neurons, 
satellite cells or lymphocytes.
The therapeutic implications o f these statements are discussed in Chapter 6 .
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2.4.2 Virus replication
The result o f these events is the ftision o f the envelope of the vim s and the target cell membrane 
which allows the release o f tegument proteins and the capsid into the cell. By analogy with 
HSV, it is possible that VZV releases into the cytoplasm a host shut down protein (such a 
protein in HSV is encoded by the homologue o f VZV ORF 17, but no host shut-down activity 
has been demonstrated in VZV). The nucleocapsid travels to the nucleus, locates nuclear pores 
and releases through them the viral genome. The nucleocapsid is accompanied to the nucleus 
by a number o f tegument proteins needed for the tr anscription o f immediate early (IE) genes. 
Among these are ORF 1 Op, and the IE proteins encoded by ORFs 4, 62 and 63.
The IE gene products brought into the nucleus are required to transactivate the expression o f IE 
genes; this is most certainly true about IE62. Once IE gene products have been synthesised in 
the target cell and transported to the nucleus (it is known, for example, that IE62 causes nuclear 
localisation o f IE4; for more details see Table 2 o f [92]), expression o f early (E) genes can 
proceed.
These are the main enzymes comiected with DNA synthesis (ORF28p, 0RF16p, ORF29p, 
ORFSlp) and the “luxury” ORF36p, which is a non-essential thymidine kinase, ORF 18p and 
0RF19p, subunits o f ribonucleotide reductase, ORF 13p, a thymidylate synthetase, as well as 
ORF47p and ORF6 6 p, the protein kinases. These proteins are also transported into the nucleus 
to participate in VZV DNA replication.
VZV DNA replication is a four-stage process, involving (i) circularisation of the linear VZV 
DNA; (ii) replication and isomérisation by homologous recombination between the inverted 
repeats; (iii) more extensive replication by the ‘rolling circle’ mechanism; (iv) cleavage o f con- 
catemers to generate linear viral DNA. The origin o f replication is located between ORFs 62 
and 63 and contains at its centre an essential 45-bp palindromic sequence (TA)iy.
In the late phase, nucleocapsid and tegument proteins (ORF 1 Op and ORF40p) and glycoproteins 
are synthesised in the cytoplasm while the nucleocapsid is assembled with the viral genome
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wrapped inside it, in the nucleus of the infected cell.
2.4.3 Assembly and egress
Finally, by mechanisms that are not at all clear, the whole virion is assembled and released from 
the cell presumably by exocytosis. There are basically three hypotheses to explain how the 
naked nucleocapsid in the nucleus acquires its outer coating of tegument and membrane with 
the right assortment o f glycoproteins:
(A) Nucleocapsids acquire their envelope by budding at the inner nuclear membranes; other 
parts o f the outer coating o f the virion accrue from vesicles foiined at the outer nuclear mem­
brane or the endoplasmic reticulum. This mechanism raises more questions than it answers; for 
example it is not clear how the glycoproteins would find their way to the nucleocapsid.
(B) The envelopment/disenvelopment/secondai-y envelopment theoiy postulates that the nucleo­
capsid, enveloped in the inner nuclear membrane, sheds it in the cytoplasm, and buds into large 
cytoplasmic vesicles, while glycoproteins are released from the trans-Golgi network (TGN) in 
microvesicles that fuse with the cytoplasmic vesicles containing the nucleocapsid. In this model 
the fate o f tegument is not clear.
(C) This is similar to the basic envelopment/disenvelopment/secondary envelopment model (B), 
in that naked nucleocapsids are present in the cytoplasm, but they are subsequently wrapped in 
TGN cisternae containing viral glycoproteins which also bind the tegument.
2.5 VZV evasion of the host defense mechanisms
The success o f VZV in maintaining itself to all intents and purposes indefinitely in humans 
means that it has evolved a number o f effective strategies that allow it to propagate itself from 
host to host. Some o f these aim to avoid the host immune defenses. Four broad mechanisms that 
human viruses use are mentioned in [50], viz., (a) antigenic mimicry; (b) rapid viral mutation (a
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strategy favoured by the Retroviridae and the Orthomyxoviridae); (c) low antigenicity and (d) 
infecting the immune cells. The examples o f (d) given in [50], o f members o f Togaviridae and 
of Retroviridae, do not include herpes vimses, but the indications are that both (c) and (d) are 
the modus operandi favoured by VZV.
In fact, the classification o f [50] seems crude, and it is preferable to discuss the following facets 
o f VZV“ host immune system interaction:
1 . subversion o f immune system elements;
2 . neutralisation o f the innate immune response;
3 . attenuation o f the acquired immune response by decreased antigen presentation.
It is only the last o f these tlnee that is relatively well understood; somewhat misleadingly, this 
is what is commonly referred to as “immune evasion”. Thus, the discussion below of items 1 
and 2 is based on veiy imperfect knowledge obtained on viruses other than VZV. It stands to 
reason that similar mechanisms are at play in VZV infections.
2.5.1 Immune subversion
There is ample evidence [84] that the first contact o f a mucosal pathogen, be it bacterial or viral, 
with the host immune system, is tlirough various sentinel cells, m ost importantly dendritic cells 
(DCs). Dendritic cells become aware o f the presence o f the pathogen both directly, by recognis­
ing non-self antigenic patterns, or by reacting to danger signals from other cells. Recognition 
of pathogen, in a process that involves toll-like receptors [104]', leads to phagocytosis of the 
pathogen by the DC, maturation o f the DC and its migration to lymph nodes. Here it can present 
antigen to naïve T cells and elicit a T cell immune response.
'Toll-like receptors are primary trans-membrane proteins o f  immune cells that serve as a key part o f  the innate 
immune system. They are a group o f  pattern recognition receptors that bind to pathogen-associated molecular 
patterns. Stimulated by these pathogens, they convey signals to the inside o f  the cell, activating signal transduction 
pathways that result in transcriptional regulation and the stimulation o f  the appropriate immune response [34].
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Transfer o f vims from infected dendritic cells to T cells has been demonstrated [11]. This 
suggests that the vims utilises migratory capabilities o f the dendritic cells to disseminate and 
initiate a viraemia. Additionally, VZV has been shown to infect DCs that are already matured 
and to modify their immune functions [81]. This is discussed later.
2.5.2 Neutralisation of the innate immune response
A relatively recent development is the realisation that many vimses [63, 82] can neutralise the 
complement system by expressing regulators o f complement activation (RCA) proteins on the 
surface o f infected cells. In the context o f Herpesviridae, this has been documented for both 
HSV-1 and HSV-2 a-hei-pesviruses, which use the gC glycoprotein to bind and inactivate the 
C3 component of the complement system. Another well-lcnown example is the Kaposi Sarcoma 
vims (KSHV), a ^-herpesvirus, which produces a protein, kaposica, homologous to a human 
RCA.
In [79], gC negative VZV mutants have been investigated; in that work it is mentioned that 
VZV gC does not bind C3a, however, the evidence from other herpesviruses makes it a strong 
possibility that VZV utilises some mechanism of complement neutralisation.
2.5.3 Attenuation of the acquired immune response
The best understood part o f  the interactions o f  VZV with the host immune system is the influ­
ence o f the virus on T cell response [10, 15, 16]. The mechanisms used by VZV differ from 
those used by other vimses [1 0 ].
A major strategy is to downgrade MHC-I expression on VZV-infected T cells. This process 
does not require viral DNA synthesis, and is thought to be mediated by IE or E gene products. 
Compared with controls, the levels o f MHC-I expression drop by about 75% in infected T cells. 
Similar findings were observed in human melanoma cells and fibroblasts. The putative mecha­
nism by which expression of MHC-I molecules is inhibited is interference with the transport of
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these molecules through the cell.
Another mechanism is the ability o f VZV to block expression o f genes coding for MHC class 
II molecules (and thus to evade CD4 T cell response). Many types o f cell upregulate MHC-II 
expression in the presence o f IFN-7 , but this upregulation is blocked in VZV-infected cells. 
In [12] it is reported that VZV infection interferes with the IFN - 7  signal transduction via the 
JAK/STAT pathway. VZV infection inhibited the expression o f STAT 1 alpha and JAK 2 pro­
teins. For a fuller discussion o f the mechanism o f this suppression see [10, 15]. Therefore VZV 
is able to escape recognition by T cells by downregulation o f expression o f MHC class I and 
class II molecules on infected cells.
Another method o f evading detection by VZV-specihc T cells is downregulation o f expression 
o f intercellular adhesion molecule 1 (ICAM-1), which was observed, for example, in infected 
kératinocytes during zoster [85]; absence o f ICAM-1 reduces the infected cells’ antigen presen­
tation to LFA-1 bearing T cells.
VZV is also able to modify the function of mature dendritic cells. These DCs downregulate 
cell-surface CD80 and CD 8 6 , activation markers involved in the activation o f naïve T cells. The 
ability o f these DCs to induce an allogenic T cell reaction was therefore significantly reduced.
Thus VZV has an intimate and far-reaching awareness o f the immune capabilities o f the host. I 
suggest that the virus is also able to monitor host immunocompetence and may use this ability 
in maintaining latency and in reactivation (see the model in Chapter 6  for details).
In this context, it seems that work on VZV in immunocompromised hosts (HIV-positive and 
AIDS patients, such as the work reported in [1, 3], is o f particular interest.
2.6 Simian Varicella Virus
Since the work presented here also involves the Simian Varicella Virus (SVV), [9], it is appro­
priate to give a brief description o f this virus [46].
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SVV (Cercopithecine herpesvirus 7) causes chicken-pox like disease in Old World monkeys, 
symptoms being fever and vesicular rash on the face, torso and extremities. Like VZV, SVV 
can remain latent in the PNS o f the host, localising to the neural ganglia. It reactivates in a 
similar manner to VZV.
Since (see [69]) the separation o f the two vimses is relatively recent, o f the order o f 4-6 Mybp 
(million years before present), one can expect very many similarities. The SVV and the VZV 
genomes have the same (type D) genome structure; 69 SVV ORFs with homology to VZV ones 
are defined. Virions have similar morphology and protein content.
Monkeys immunised with VZV are protected against SVV challenge, which indicates very 
close antigenic relatedness o f the two viruses. However, see remarks in section 4.5 concerning 
intracellular localisation of latent SVV in neurons.
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Chapter 3
The clinical picture
In this chapter, I have two main aims. One is to describe the pathogenesis o f chickenpox, the 
primary infection caused by VZV. Since the primary aim of this research is to understand and 
control latent VZV reactivation, it is important to imderstand the processes that lead from the 
entry o f VZV into an organism to its establisliment in the PNS. The presentation of these aspects 
o f VZV function is mainly based on the work of Arvin and co-authors [10, 15, 16, 79, 80], 
whose papers should be consulted for references o f original work.
The other aim is to briefly suiwey the various neurological complications that can arise as a re­
sult o f latent VZV reactivation. VZV has a significant disease burden, especially in the elderly 
and immunodeficient subjects, therefore management o f VZV-related diseases is o f major im ­
portance in the developed world, with its aging population. In this survey I have been influenced 
in particular by references [42, 44, 53, 54].
3.1 Chickenpox
VZV primary infection manifests itself as varicella (chickenpox), a common childhood disease. 
It is estimated [53] that about 4 million cases a year of varicella occur in the US .
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Typically, mucosal surfaces are inoculated from respiratory secretions or skin lesions of carri­
ers. The virus possesses sophisticated mechanisms [10] o f subverting the host immune system 
allowing it to multiply unmolested for the incubation period o f 10-21 days. Presumably, the 
virus enters lymphatic tissue close to the locus of inoculation which leads to primary viraemia 
by infecting peripheral mononuclear blood cells (PMBCs). This allows the virus to be trans­
ported to other sites o f  early replication, such as the reticuloendothelium of the liver. There 
is evidence that in common with other alphaherpesviruses, VZV causes apoptosis in PMBCs 
[59]. A secondary viraemia follows, which is the main mechanism of virus transport to the skin, 
where the characteristic lesions are fanned.
The host immune response to the virus presence is initially restricted to NK killer cells and 
interferon-CK, but the succèssfiil resolution o f the infection is predicated on mounting a success­
ful T-cell response, involving both CD4 and CDS cells.
A contentious issue o f major importance is the mechanism of establishment o f virus latency in 
sensory ganglia. The consensus seems to be that the virus reaches the ganglia by retrograde 
transport from skin lesions. A t the same time, there is evidence, both clinical and from animal 
models (see [10] for references) suggesting a haematogeneous route, e.g. by infected T-cells 
coursing through the ganglia. Additional support for the haematogeneous route is furnished 
by the work [74] on SVV, in which SVV DNA was detected in the ganglia of experimentally 
infected monkeys before the detection o f rash; furthermore these authors also report cases in 
which there was no rash at all even though latency was established in the sensory ganglia. 
Though it appears that the case for the transport of vims to sensory ganglia by blood cells is 
convincingly made, the relative importance o f the two routes is not clear at this stage. In [41], 
presence of VZV DNA in human nodose and celiac ganglia* is reported using PCR. On the 
face of it, this is evidence for the haematogeneous route. However, these authors also report 
the presence o f  HSV-I DNA, for which vims no such route exists. Hence it seems that this is
’The nodose ganglion is the sensoiy ganglion o f  the tenth (vagus) cranial nei-ve. It contains cell bodies whose 
axons are part o f  the autonomic nervous system that provides Abi es for taste as well as cell bodies whose axons 
innervate the heart, bronchi and viscera. Celiac ganglia are part o f  the sympathetic nervous system that supply the 
spleen and multiple viscera.
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a crucial open question, since clearly, if the retrograde transport o f virus from skin lesions is 
important, local treatment with antiviral agents, or something less crude that would impede this 
transport would immediately (and cheaply) alleviate the infection burden. Some ideas how this 
could be done are contained in Chapter 6 .
In the cotton rat model [95] it is shown that replication-deficient mutants can still establish 
latency. In this work ([8 ] and work in preparation), rats inoculated in the footpad express VZV 
genes in lumbar and thoracic ganglia. These findings indicate that in these animal models direct 
viraemia is an important mechanism of VZV dissemination.
3.2 Zoster
Following the primary infection, VZV can remain latent in the host, residing in cranial (trigem­
inal), dorsal root and autonomic ganglia (see the reviews [29, 53, 55] for references to the 
original work). It is estimated that 90% o f normal individuals carry VZV DNA.
Latent VZV can reactivate. The incidence o f reactivation grows with age of the host and is 
higher in immunocompromised individuals, such as those with cancer, organ transplant recipi­
ents and AIDS patients [29].
On reactivation, the vims produces primarily shingles (herpes zoster). The original observa­
tion that it is in fact the same virus which causes both chicken pox and shingles was made by 
Hope Simpson in 1954 when clinical observation indicated that varicella developed in children 
exposed to a relative with zoster, and experimentally by the inoculation o f children with zoster 
vesicle fluids (reviewed by Breuer [21]). He hypothesised that if  the viruses were the same 
the clinical behaviour should be indistinguishable, including incubation period, infectivity and 
protection against subsequent chickenpox but not other vimses. An outbreak o f chicken pox on 
the remote island o f  Yell enabled him to establish that indeed these conditions were fulfilled. It 
is estimated that more than 500,000 cases o f zoster occur in the US alone annually [44].
That it is the vims latent in the sensory ganglia, the reactivation o f which causes zoster, and not
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a de novo primary infection, has been demonstrated in the classical paper o f Straus et a l  [99].
Zoster is a painful eruption o f skin, covering one or more dermatomes. It is characterised by a 
severe sharp pain. The sensation in the affected dermatomes is reduced, but the skin is extremely 
sensitive to touch. The progression of disease is usually from thoracic herpes followed by 
facial lesions. Other organs can be affected, such as eyes (zoster keratitis, which can lead to 
blindness, ophthalmophlegia, optic neuritis), parts of the head innervated by the maxillary and 
mandibular divisions o f the trigeminal neiwe (leading to osteonecrosis o f the jaw  and exfoliation 
o f teeth), or the ear (zoster oticus). Facial muscle weakness is not uncommon (for example, the 
Ramsay-FIunt syndrome which expresses itself as zoster oticus combined with peripheral facial 
weakness). Cases of cervical zoster and o f zoster-associated arm weakness (zoster paresis) 
have been also reported. The usual treatment for zoster involves a combination of acyclovir and 
analgesics.
3.3 Complications of zoster
These are numerous and can be painful and sometimes life-threatening. In addition to the ones 
described in some detail below, VZV has been implicated in the Gillain Barré syndrome [54] 
and genital herpes [19].
3.3.1 Postherpetic Neuralgia
Postherpetic neuralgia (PHN) is the most important complication o f zoster infection and has 
been defined as dermatomal pain persisting for more than 4 -6  weeks after the rash. However 
there is no universal consensus as to the exact time definition o f PFIN with some definitions 
varying between 1-6 months. PHN is characterised by the development o f chronic hyperalge­
sia (increased response to noxious stimuli) and allodynia (pain in response to imiocuous stimuli) 
accompanied by spontaneous pain o f a burning or aching nature. Ninety five percent o f PHN 
cases are in those aged over 60. Over 40% of patients with zoster develop PHN. The incidence
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of PHN is apparently slightly greater in women and following trigeminal distribution zoster. 
No clear understanding o f the aetiology o f this debilitating condition exists. The detection of 
VZV-specihc DNA in the mononuclear cells (MNCs) o f patients with PHN is suggestive o f 
the persistence o f VZV. One study ([71]) has indicated that the abundance o f VZV DNA in 
ganglia is higher in PHN patients than in zoster patients without PHN. Therefore it is possible 
that MNCs trafficking through these ganglia may engulf virus whose DNA is then available for 
extraction and amplification by PCR. A greater virus burden or a productive infection found 
in these ganglia in PHN compared to latency [73], would provide a rationale for aggressive 
treatment with antivirals. The existence o f ganglionitis without rash has been supported by the 
presence o f radicular pain up to 100 days preceding zoster, pre-herpetic neuralgia [40]. Further, 
a report [38] has described patients with acute trigeminal distribution zoster who, after years 
free from pain, developed severe trigeminal PHN. It should be appreciated that permanent ab­
normalities o f neuronal electrophysiological activity may also be important in the pathogenesis 
o f PHN, irrespective o f any persistent virus infection [53].
3.3.2 VZV vasculopathy
On reactivation, VZV can spread to arteries in the brain and the spinal cord. Both large and 
small vessels can be affected. Large vessel vasculopathy is more characteristic of elderly im­
munocompetent patients. Large vessel encephalitis is fatal in up to 25% o f cases. Angiography 
reveals focal constriction and segmental narrowing. Small vessel vasculopathy is more often 
seen in immunocompromised individuals and is accompanied by headaches, fever and mental 
state changes [42].
3.3.3 VZV myelitis
This is another serious (in immunocompromised patients) zoster complication the mechanism 
o f which is unknown. It can be acute, cluonic or recurrent. In severe cases, spinal cord necrosis.
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inflammation and parenchymal VZV invasion are observed.
3.3.4 Zoster sine herpete
This term refers to zoster-associated pain without antecedent rash [48]. Involvement of VZV 
in these conditions was verified by detection o f VZV DNA and antibody in cerebrospinal fluid 
o f patients (see [44] for references to the clinical work). Similar findings, o f VZV genomes 
without dermatological evidence of reactivation, were made in cases o f unilateral facial palsies, 
meningitis and meningoencephalitis.
3.4 VZV reactivation following HCT
There is frequent VZV reactivation following hematopoietic cell transfer (HCT) [15]. Clearly, 
HCT recipients are immunodeficient, which makes reactivation more likely even without HCT 
(from the presentation of [15] it is not clear how frequent reactivation is in patients requiring 
HCT before treatment ); this would explain the prevalence of herpes zoster in such patients. 
However, neuropathic pain and disseminated VZV infection without skin lesions indicate that 
cells pick up the virus while trafficking through infected ganglia.
3.5 VZV and GCA
It is well documented that, in the process o f cell to cell spread, VZV has the ability to fuse 
cells into syncytia, the mechanism of which seems to involve glycoproteins such as gE [57]. 
In addition, cumulative evidence suggests that VZV can infect the walls o f CNS arteries. It is 
hypothesised that VZV spreads from ganglionic reactivation sites to the arterial wall by neural 
pathways [75]. Hence it is reasonable to suspect VZV involvement in the aetiology of diseases 
that present syncytia in inflammatory infiltrates. One such disease is giant cell arteritis (GCA).
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VZV involvement in this disease has been a matter o f some debate. Helweg-Larsen et al. [47] 
looked at 13 GCA-positive biopsies and 17 controls and found no evidence o f VZV by PCR. 
Mitchell and Font [78] looked at 35 GCA and 29 normal biopsies and found that 9 (26%) were 
positive by PCR. In [8 6 ] more sensitive methods were used and in none o f the 10 GCA biopsies 
was any evidence o f VZV DNA or antigen foimd. Thus the evidence for VZV involvement in 
GCA is contradictory and in need o f clarification.
?
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Chapter 4
VZV latency
This chapter contains a discussion o f the the cellular localisation o f latent VZV, patterns of gene 
expression in latency and factors influencing reactivation.
4.1 Cellular site of latent VZV
It is well established [92] that the virus establishes latency in trigeminal (TG) and dorsal root 
ganglia (DRG) o f the PNS (where like HSV-I it is found in an episomal state). A priori there 
could be two reasons for that. One is that in the cells o f the PNS the virus is well-protected 
from the cell-mediated components of the host immune system, while the other is that the cells 
harbouring it camiot support a productive lytic cycle. The evidence o f reactivation suggests that 
only the first o f these is true, i. e. that the virus hides in a compartment that will allow it to 
weather the period o f extreme immunosurveillance. I f  this is the case, there must be information 
traffic between viral control components and the outside o f  the harbouring cell. This may be 
the (tacit) paradigm o f VZV latency. Neurons are good candidates for a hiding place for a latent 
virus as they express almost no MHC class I molecules and so the cell is protected from CD8  T 
cell elimination. Also HSV-1 resides in neurons [33] so their homology and other similarities 
might suggest that there is a common site o f latency for both.
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The exact localisation of latent VZV in TG and DRG has been a topic o f much debate. A 
good review of the histoiy of this controversy and the relevant references are contained in [53]. 
Briefly, historically there have been two schools o f thought, one suggesting that VZV is latent 
in neurons exclusively, and the other, that it resides as exclusively in non-neuronal (such as 
perineuronal satellite) cells. The earliest paper to use ISH to localise VZV [49] reported VZV 
RNA in neuronal cytoplasm in latently infected TGs. This was confirmed in 1987 by the same 
group [100] and independently in [43]. However, a further study using labeled riboprobes 
indicated the presence o f latent VZV exclusively in perineuronal satellite cells [33], which was 
confirmed in 1993 in a further study from the same laboratory [77]. A study using the sensitive 
technique o f in situ PCR hybridisation [37] found latent virus DNA exclusively in the cytoplasm 
o f neurons. An important paper on this subject is the study by Lungu et al. [65] who found 
VZV DNA in both types of cells though in higher numbers than expected from quantitative 
studies [89, 73, 30].
One o f the major goals o f this research was to resolve this controversy to the satisfaction of all 
the relevant researchers in the field and, as will be shown below, we accomplished that goal.
4.2 VZV gene expression during latency
While in HSV-1 the only transcripts found to be expressed during latency are the latency- 
associated transcripts that are partially overlapping and complementary to the transcriptional 
activator ICPO, the general consensus is that during VZV latency, VZV genes 21, 29, 62 and 
63 are expressed, with some evidence of expression of genes 4, 18 and 6 6  as well (see, for 
example, [32]). The original studies o f transcription [33] used ISH and Northern blotting which 
detected transcripts from genes 29 and 62 but not 28 or 61. Subsequently VZV transcripts for 
VZV gene 21 were identified in TG and DRG [28]. The expression o f genes 21, 29, 62 and 63 
has been confirmed using cDNA libraries [27, 31] and in situ hybridisation [77].
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In vitro and animal model studies indicate that many o f the genes expressed in latency, such as 
0RF21 [106], and others such as ORFs 47 and 6 6  [95], ORF2 [94] and ORF61 [96], are not 
necessaiy for the establishment o f latency.
4.3 Protein expression in latency
Unlike latency in HSV-1, where no proteins are expressed, latent VZV expresses a number o f 
gene products. There have been several reports of expression o f VZV gene 63 encoded protein 
[36, 72]. Lungu at a l  [6 6 ] in 1998 were the first to report the presence o f proteins encoded 
by VZV genes 4, 21, 29, 62 and 63. These proteins have been found in the cytoplasm of the 
latently infected neurons, leading the authors to propose that the restriction o f these regulatoiy 
proteins from the nucleus interrupts the cascade of events leading to a productive infection and 
results in latency.
4.4 Reactivation
There is very little information on what causes reactivation o f latent VZV. In [107] a correlation 
between the amount o f UV irradiation and frequency is established; in [76] a case study with 
astronauts implicates stress as another possible factor. Since it is well known that reactivation is 
enhanced in the immunocompromised, such as HIV positive, patients, one needs to understand 
the immune response raised by the host to VZV; furthermore, since immune dysregulation is a 
common result o f stress, and since stress is implicated in reactivation, it makes sense to connect 
the dysregulation caused by stress and VZV reactivation.
Both MHC-I restricted and MHC-II restricted cells are sensitised during primary infection with 
VZV [10]. The T cell response is predominantly Thl type and is characterised by a high level 
o f IFN-7 . VZV-specific CD4 cells also exhibit MHC-II cytotoxicity against infected cells. Loss 
o f VZV-specific T cells is thought to increase the risk of reactivation [10].
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This scenario meshes well with what is loiown about immune dysregulation following stress. 
For details the reader is referred to [8 8 ]. The relevant facts are that stress-induced release of 
catecholamines can result in the suppression o f IL-12 production and the increase of IL-10 
production, a shift in the phenotype o f CD4 T cells from Thl to Th2 and decrease in IFN - 7  
production.
I shall use the above data to produce a rudimentary latency maintenance and reactivation model 
below.
In [60], in a 4 year follow-up study it was claimed that vaccination with the Oka strain leads to 
frequent asymptomatic reactivation. Thus it is possible that the vim s reactivates spontaneously 
much more frequently than indicated by the occurrence o f zoster, but is dealt with efficiently 
by an immunocompetent host. The explanation given in [60] for their findings have been hotly 
disputed, with some researchers such as [97] claiming that the increase in titre in vaccines was 
due to exogeneous boosting.
4.5 Animal studies
Major limitations o f animal models are that they are critically inoculum dependent and VZV is 
difficult to grow to high titre, and the fact that no in vivo animal model has shown reactivation
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There have been several reports in the literature (reviewed in Myers and Connelly [83]) o f 
animal models in primates where infection induced seroconversion but no disease was produced 
or vims recovered. Weanling guinea pigs have been used to evaluate humoral and cell-mediated 
response as they undergo a limited viraemic infection. However, the model is inconsistent. 
Rabbit eye models have also been investigated and no clinical illness obseiwed. A scid-hu 
mouse model where human thymus, liver or skin implants were engrafted into male CB-17 
scid/scid mice has proved useful in assessing contributions o f gene products to VZV replication 
in intact human tissues containing differentiated skin and T cells (see, e.g. [17]). There have 
also been isolated reports on neonatal rat models and mouse models.
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of VZV, though recently [22] there has been a report o f an in vitro guinea pig enteric ganglion 
model which may prove useftil as it appears to mimic some of the properties o f latency, includ­
ing reactivation o f virus when non-neuronal cells are added to the neuronal cell populations. In 
the Liège group rat model (e.g. [7, 93]), inoculation o f VZV-infected Vero cells in both foot­
pads leads to seroconversion but no symptoms o f disease; latency was characterised by vims 
genome persistence in the DRG for many months, selected viral transcription and at least one 
viral protein. Reactivation has not been obtained in vivo, but has occurred ex vivo after repeated 
stresses. Many similarities with VZV latency in humans were found, making this model useful 
for vaccine and antiviral studies.
Finally, SVV in primates has been investigated as a putative VZV model as it has many simi­
larities to VZV in humans. Initially, experiments were performed on intratracheally inoculated 
African green monkeys [74], but it was found that vims DNA was still detected in ganglia, 
liver and blood MNCs, primarily in CD4-F and CD8 -H cells, months to years post infection. 
Therefore this is a model of persistence rather than latency. More recently, naturally infected 
monkeys, that is SVV-seronegative monkeys which have been exposed to SVV by being placed 
in cages with SVV-intratracheally infected monkeys, have been described [70, 9]. These mon­
keys developed mild varicella 10-14 days post infection and SVV DNA persisted at multiple 
levels o f the nemaxis but not in lung or liver 6 - 8  weeks later, thus providing a possible model 
o f latency. This model may have more relevance to the human situation [70, 9].
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Chapter 5
Results
This chapter describes the contribution o f the work I have carried out in Professor Kennedy’s 
laboratory to VZV lateney studies.
5.1 Studies of VZV lateney in humans
5.1.1 Cell localisation of latent VZV
Given the controversy about the site o f latent VZV in the human PNS as described in the previ­
ous chapter, paper [1] addressed this issue using trigeminal ganglia (TG) samples from a number 
o f different laboratories, run by people who took opposite sides in the localisation debate. This 
study used a large number o f subjects (30; 2 neonates, 11 individuals with tllV  infection and 17 
immunocompetent individuals) with the results being confirmed by multiple techniques. VZV 
DNA in ganglia was detected in 15 individuals by using PCR alone, and in 12 individuals (6  
normal non-HIV and 6  positive HIV individuals, but not neonatal ganglia) by using ISPCR. 
W hen ISH alone was used, 5 HIV-positive individuals and only 1 non-HIV individual showed 
VZV nucleic acid signals in ganglia. Oligonucleotide probes and primers to VZV genes 18, 21, 
29 and 63 were used. In situ PCR enabled the detection o f VZV DNA in an additional 5 im-
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mimocompetent and 1 HIV-infected individual compared to in situ hybridisation (ISH). Using 
ISH and ISPCR in a blind study where the source of the ganglia was unknown, it was shown 
conclusively that latent VZV is largely concentrated in the nuclei o f (2% -5% ) neurons with 
only a negligible number of satellite (glial) cells (<  0 .1%) infected.
An extended study on DRG using ISH and ISPCR was conducted on 12 individuals (3 normal 
and 9 HIV-infected) [2], with comparable results, i.e. 2-5%  of neuronal nuclei and only occa­
sional non-neuronal cells were positive for VZV DNA and two regions o f the genome (gene 4 
and 40) were present in serial sections.
5.1.2 Studies of gene transcription
I have also conducted studies o f VZV gene expression in latency. Evidence o f the transcription 
o f VZV genes 4, 21, 29 and 63 in the DRG [2] was found by ISH, consistent with the results 
o f others. In addition the co-localisation o f DNA and RNA for gene 29 was shown in serial 
sections. In paper [3], ISH was used to determine the frequency o f RNA expression for 9 VZV 
genes in TGs o f 35 human subjects, 18 o f whom were HIV positive. RNA for VZV gene 21 was 
detected in 7/11 normal and 6/10 HIV positive subjects, gene 29 in 5/14 normal and 11/11 HIV 
positive subjects, gene 62 was detected in 4/10 normal and 6/9 HIV positive subjects and gene 
63 in 8/17 normal and 12/15 HIV positive subjects. RNA for VZV gene 4 was detected in 2/13 
normal and 4/9 HIV positive subjects and gene 18 4/15 normal and 5/15 HIV positive subjects. 
RNAs for VZV genes 28, 40, and 61 were rarely or never detected. In addition VZV gene 63 
encoded protein was detected mostly in the cytoplasm of 25% of TG from HIV-infected and 
normal cases.
I also participated in a study o f expression of VZV ORF6 6  [4] in association with R. Cohrs and 
D. H. Gilden in Denver. This is an important gene to investigate, as its product, ORF6 6 p, (a 
protein kinase) has been shown to be responsible for the phosphorylation o f ORF62p and its 
cytoplasmic localisation [58]. VZV ORF6 6  transcripts were detected by RT-dependent, nested 
PCR and ISH. Twenty seven ganglia from 22 individuals were analysed by ISH for transcription
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o f VZV genes 6 6  and 62. In serial sections from 5 ganglia, transcripts from both genes were 
detected in neuronal nuclei. In one case VZV gene 62 was detected in the absence of VZV 
gene 6 6  RNA. In addition VZV ORF6 6 p was located by in situ histochemistry in the neuronal 
cytoplasm o f 3 TG o f 11 studied (from 7 subjects).
5.1.3 Detection of VZV-encoded proteins in latency
In paper [5] we detected and thereby confirmed the presence o f ORF21p, ORF29p, 0RF21p, 
ORF62p, ORF63p in the neuronal cytoplasm. A total of 10/22 ganglia were positive for VZV 
21p, 9/23 for VZV gene 29p 5/5 for gene62p and 10/10 for gene 63p. Positive labelling was 
predominantly in the neuronal cytoplasm, but not in non-neuronal cells. In 2 samples there was 
also neuronal nuclear staining. Approximately 5-10% o f neurons were positive. In addition, as 
described above, ORF6 6 p has been detected in neuronal cytoplasm [4].
5.1.4 Disease study: GCA
In order to study VZV involvement in GCA [6 ], in situ PCR for VZV genes 37 and 62 and ISH 
using DIG-labelled probes for VZV genes 37 and 62 were used in an attempt to detect VZV 
DNA in arteries from 15 histologically proven GCA and 7 nonnal controls. No VZV DNA was 
detected in artery tissue.
5.2 Studies of animal models of VZV latency
5.2.1 Studies of the Liège rat model
In paper [7], an ISH study in a rat model was conducted in a total o f 23 rat DRG from 16 
animals, and it was demonstrated that VZV DNA was found almost exclusively in (5% -10%  
of) rat DRG neurons. Gene expression in ganglionic tissue was also studied at multiple time
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intervals (1 week, 1 month and 18 months) after footpad inoculation with VZV. As in humans, 
expression o f VZV genes 21, 62 and 63 was found.
In addition in situ PCR and ISH were used to detect VZV DNA and ISH to detect VZV RNA 
were used in an investigation o f whether the deletion o f gC and gl were required for the es­
tablishment o f latency in the rat model [8 ]. Transcripts corresponding to the three classes of 
genes ORF 4, 62 and 63 (IE) ORF 18, 21 28 and 29 (E) and ORF 40 (L) were studied in 27 
DRG from 20 rats that had received footpad inoculation with different mutant VZV at 1 week, 1 
month and 18-24 months post inoculation. VZV DNA and RNA were detected in neuronal and 
non-neuronal cells with transcripts for VZV genes 62 and 63 being the most frequent at 18-24 
months for both mutants. Transcripts for VZV gene 40 were not detected. .
5.2.2 SVV gene expression in latency
Using the natural model of SVV infection described in section 4.5, two months after natural 
infection with SVV, African green monkey ganglia (18 ganglia from 2 animals) were analysed 
using DNA ISH and ISPCR for SVV genes 21 and 63. Seven ganglia o f 9 tested from one 
animal and 4/9 from another were positive by ISH and a further 5 ganglia were positive by 
ISPCR. In addition, it was found that neuronal cytoplasm was the predominant site of SVV 
genome localisation [9].
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Chapter 6
Discussion
It can be concluded from initial detailed studies that the neuron is the predominant site of 
latent VZV in human trigeminal ganglia. The localisation results contained in [1], as well 
as confirming the initial observations in the Gilden laboratory, have been confirmed by an ISH 
study in TG [102], and by studies such as [62, 64], in which ganglia were dissociated into pure 
populations o f nemonal and non-neuronal cells and then PCRs for VZV DNA were performed. 
In addition, our work was confirmed in the laboratory o f S. E. Straus, where the original work 
claiming that VZV was latent in the peri-neuronal satellite cells was performed (see [89], and 
Proc. International Heipesvims Workshop, Reno Nevada, July 2004). Thus it is now universally 
accepted that this work has resolved the controversy o f the localisation of latent VZV. A related 
question is that o f VZV burden, that is, of the number of copies o f VZV genome per infected 
cell. My results o f 2-5%  of neurons containing VZV DNA are consistent with approximately 8 
copies per infected neuron [53], which is comparable to the results obtained for HSV-1 which 
have been calculated in other studies such as [73, 89]. Consistent with this are the results o f 
[62] and [64] described above, where viral DNA was found to be present in about 1.5% of 
neurons, but in no non-neuronal cells; their computation o f VZV burden gives 2-9  copies o f 
viral genomes per infected cell. In the paper o f  Cohrs et al. [30] the use o f real time PCR for 
the detection o f VZV nucleic acids showed for the first time the variable abundance o f VZV
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The work presented in [1] also compared the burden o f immunocompetent patients to that of 
HIV-positive ones and found it to be larger in the immunocompromised population (for non- 
AIDS tissue the presence of viral DNA was usually detectable only by in situ PCR, whereas for 
HIV-positive tissue, ISH was sufficient for detection).
The initial studies in our laboratory on localisation and expression o f VZV in DRG [2] con­
firmed that genes 4, 21 29 and 63 were expressed and in addition occasionally VZV gene 18 
was expressed. This, along with the fact that 2 disparate regions o f the genome (genes 4 and 
40) were detected in the same region o f tissue on serial sections indicate that the entire genome 
was present. DNA and RNA for VZV gene 29 were also present on serial sections in the same 
region o f the DRG. Ideally one would show both in the same cell by double labelling but this 
proved to be technically difficult.
The frequency o f RNA expression for 9 VZV genes in TGs of 35 human subjects, 18 o f whom 
were HIV positive [3] was studied. Genes 21,29, 62 and 63 were detected with high frequency, 
confirming the results o f previous studies, and RNA for genes 4 and 18 with lower frequency. 
RNA for genes 28, 40 and 61 was not detected, suggesting that they are unlikely to be latency- 
associated genes. In all cases, the immunocompromised subjects showed higher rates o f gene 
expression but no significant expression o f additional genes.
It has been estimated that 87% of human TGs from seropositive individuals contain VZV DNA. 
Unfortunately, since post-mortem tissue must be used, the theoretical possibility that viral reac­
tivation may have occurred after death or on ganglion removal, exists. Therefore any study of 
loealisation or transcription of VZV during latency must be interpreted with caution. To address 
this problem, explanted fresh TG and DRG were cultured for up to 11 days and the pattern of 
gene expression in explanted tissue was investigated. Interestingly, in addition to frequent ex­
pression of genes 29 and 63 (which is now considered the hallmark o f latency), we found high 
levels o f genes 18, 28 (both E genes), and 40. This indicates that what is seen in latency studies 
is true latency and not the result o f viral reactivation upon excision o f tissue. The detection of 
ORF40 requires special comment. ORF40p is a nucleocapsid protein, and ORF40 is a late gene.
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In at least one sample ORF40 RNA was detected only after 168 hours o f explantation, without 
being detected earlier. It is very probable that this is the most complete portion o f a productive 
lytic cycle from a tissue explanted post-mortem. It seems to us that many more studies o f this 
sort are required (for example, checking co-expression o f ORF 18 and ORF 19).
In addition this paper contained the first demonstration o f positive staining with a monoclonal 
antibody to VZV 63p. Approximately 25% o f samples investigated showed positive cytoplas­
mic staining in neurons, with very occasional staining in neuronal nuclei or non-neuronal cells. 
These results confirm the importance of VZV gene 63 in latency and support the previous stud­
ies indicating significant and restricted gene expression in latency.
I also participated in a study o f expression of VZV ORF6 6  [4]. This is an important gene to 
investigate, as its product, ORF6 6 p, (a protein kinase) has been shown to be responsible for 
the phosphoiylation o f ORF62p and its cytoplasmic localisation [58]. VZV ORF6 6  transcripts 
were detected by RT-dependent, nested PCR and ISH. Our group performed the ISH experi­
ments and located VZV ORF6 6 p in neuronal cytoplasm by in situ histochemistry. This was the 
first demonstration of VZV gene 6 6  expression in latency; it raises the possibility that the co­
expression o f these genes and the location o f ORF6 6 p may play a role in latency establishment. 
Since the activation o f VZV gene transcription takes place in the nucleus, the phosphorylation 
of ORF62p by ORF6 6 p, a protein kinase, leading to cytoplasmic localisation o f ORF62p, may 
modulate its ability to transactivate, which in turn may play an important role in the establish­
ment o f latency.
In the study o f the translation o f VZV genes during latency [5] the results o f one other study 
[6 6 ] were confirmed in a larger sample size and using one monoclonal antibody. Unfortunately, 
these results could not be confirmed by Western blotting (experiments carried out by R. Cohrs 
and P. G. E. Kennedy), indicating a probable low abundance o f VZV proteins; however it does 
lend support to the finding that these proteins, which localise to the nucleus o f cells during 
lytic infection, are detected in the cytoplasm o f latently infected neurons. The restriction o f 
regulatory proteins from the nucleus o f latently infected neurons might interrupt the cascade of
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virus gene expression that leads to a productive infection.
In order to study VZV involvement in GCA [6 ], ISPCR and ISH were used to tiy to detect VZV 
DNA in arteries from histologically proven GCA and of normal controls. No VZV DNA was 
detected in artery tissue, a result which should stiengthen the case for the non-involvement o f 
VZV in GCA and direct the search towards other syncytia forming viruses or other possible 
aetiologies. Recently a PCR based study involving 147 GCA biopsies found no evidence o f 
VZV, confirming our results [90]. It should be noted, however, that the absence o f VZV does 
not preclude a possible role for VZV in the initiation (not the propagation) o f the disease.
In these studies, we have also extended the miderstanding and utility o f the rat model of VZV 
latency establishment using both wild type and mutant viruses [7, 8 ]. In [7], using ISH foi 8 
different genes representing the 3  classes o f infection, the pattern o f viial gene expiession at 
1 week after infection (where many genes were expressed) was different from that obseiwed 
after 1 and 18 months. The results obtained, o f limited gene transcription similar to the human 
situation, even 18 months post inoculation goes some way towards validating the rat model 
as a viable model o f VZV latency. PCR in situ amplification was also used to determine the 
cell specificity o f latent VZV DNA. Obviously, the results do not perfectly mirror the situation 
in human tissue as larger numbers of cells are infected and in particular, a laigei number o f 
non-neuronal cells have both VZV DNA and RNA (at an approximate ratio o f 3 : 1). Immuno- 
histochemical studies using monoclonal antibodies established the presence of ORF63p in both 
nuclei and cytoplasm o f the infected cells. This study also confirms the importance of VZV 
gene 63 expression and translation in VZV latency.
In a later study o f the same model [8 ], deletion mutants o f glycoproteins gC and gl (encoded by 
ORFs 14 and 67, respectively) were used to see whether these gene products are needed foi the 
establishment o f latency. Using the expression o f genes 2 1 , 29, 62 and 63 as indicating latency, 
it was concluded that these two genes are dispensable for the establishment o f latency in rat 
DRGs. This study complements the mutant work done in vitro and in the cotton rat model o f 
Cohen [94, 95, 96, 106] in which infected melanoma cells are injected intramuscularly along
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both sides o f the thoracic and lumbar spine. In these studies DNA and RNA are extracted from 
the ganglia after one month and PCR is performed. Presence o f ORF 63 transcripts and the 
absence o f ORF 40 transcripts is taken to signify the establisliment o f latency
Using DNA ISH and DNA in situ PCR for simian varicella virus (SVV) genes 21 and 63, it 
was found that neuronal cytoplasm was the predominant site o f SVV genome localisation [9]. 
It is possible that SVV has diffused from the nucleus during the harsh procedures o f ISH and 
ISPCR, or there may indeed be significant biological differences in the latency process due to 
differences in viral and/or host factors. This supports the use o f natural infection with SVV as 
a model for VZV latency.
O f all the results concerning deletion mutants, the result of [95] concerning ORF6 6  and my own 
study o f ORF 14 [8 ], which show that ORFs 6 6  and 14 are dispensable for the establisliment of 
latency, are the most interesting for a number o f reasons. First, since ORF6 6 p is instmmental in 
localising ORF62p in the cytoplasm, and ORF62p seems a likely candidate for a latency main­
taining protein (LMP), this result, if  confirmed in other systems, should indicate that latency 
establishment and maintenance are different processes. It would be particularly interesting to 
know whether ORF6 6  deficient mutants reactivate with the same efficiency as the wild strain. 
Concerning 0R F14p, gC, recall that in the SCID-hu mouse model [79] gC was responsible for 
skin tropism. It is possible that the establisliment o f latency in the rat model by gC-negative 
mutants is an indication that in that model the haematogenic route for latency establishment is 
the dominant one, but whether this has any implications for the situation in vivo is not clear.
Methodologically, the study o f VZV latency is in a very unsatisfactoiy state. There do not seem 
to be any competing hypotheses to explain any of the known facts o f viral gene expression. (The 
only relevant model I have come across is the one of Cohis and Gilden [29]: “. . .  during latent 
infection sequence-specific binding o f 21p/29p complex inhibits IE62 transactivation o f ORFs 
20 and 28.” Clearly something more encompassing is called for.) The usual strategy, especially 
using deletion mutants, is o f the “try and see” type.
First o f all, the following question has to be confronted. If  the maintenance o f the VZV latent
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State is somehow related to the gene products expressed in the latent state, which seems likely 
(to argue otherwise would seem to be a violation of parsimony principles but it is conceivable 
that the sequences are being transcribed by accident, because they are able to be transcribed 
because o f histone patterns or are an epiphenomenon), why does HSV express nothing but the 
latency-associated transcript (LAT). There are two possible answers to this question. Fiist, a 
less elegant solution, is as follows. Since the morphology is more or less conseived through 
the alphaherpesvims families, it is very possible that HSV brings in its nucleocapsid sufficient 
amounts o f LMPs not to need to synthesise them de novo. Since all proteins have finite life-span, 
there must be also a mechanism to make LMPs invisible to the cell proteolytic machinery. The 
second answer is that FISV is more sophisticated virus than VZV and that HSV latency, once 
established, is maintained by subverting host control elements. Very recent findings, published 
after this thesis was submitted, indicate that ORF63p is critical for the establisliment o f latency 
in a rodent model [25, 26]. I conclude this section by outlining a possible model for VZV 
latency. It postulates the virus being capable of interpreting information concerning the state of 
the host’s immunocompetence. The model assumes that establislnnent o f latency is not crucially 
dependent on the host’s immunocompetence, though this is not difficult to take into account by 
remembering that the regulatory proteins such as ORF62p are tegument proteins and so can 
change conformation, e. g. by contact with various interleukins and bring this information into 
the host cell thus deciding on the immediate fate o f the virion. In fact it is known [10] that T 
cells induced to proliferate and secrete cytokines during primary infection recognise ORF62p. 
This model is based on the following assumptions:
1. The interior o f the neuron, more precisely the neuronal cytoplasm gives a faithfiil represen­
tation o f the host’s generalised immunocompetence. For example, the amount of extracellular 
IFN - 7  or ILs 2 or 12 could be communicated to the interior o f the neuron. That, at least in 
fibroblasts this is indeed true in the case o f IFN-7 , and that VZV can interfere with this particu­
lar signal transduction pathway, is known from the work o f Abendroth and Arvin [10, 12]; see 
section 2.5.3 for details.
2. This information, which correlates with the host ability to mount an anti-VZV cell-mediated
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response, is available to VZV “sentinel proteins”, the best candidate for which now is ORF62p, 
IE62. This picture is consistent with its cytoplasmic localisation in latency. It is cmcially 
important to be able to characterise ORF62p interactions with ILs and with cellulai factois.
If  this picture is coiTect, I would predict that ORF62 mutants would not be as sensitive in 
reactivation.
3. When there is some evidence o f immune dysregulation (see section 4.4), for example, if IL- 
12 levels are depressed and IL-10 levels are raised, this information is passed on to the cellular 
sites where the VZV genome is sequestered and the lytic cycle is started. This view is consistent 
also with the high level o f co-occurrence o f VZV reactivation and autoimmune disease episodes 
and in fact with the folklore view o f the immune system, viz. that boosting the immune system 
”in general” helps prevent specific disease.
Some researchers (see e.g. [10]) explicitly state that risk o f reactivation is inversely proportional 
to the numbers o f circulating VZV specific T cells. However, this does not contradict the view 
presented here, since these numbers would depend on the general level o f host immunocompé­
tence. Furthermore, I would like to quote from a paper by Arvin [15]:
Despite the correlation between loss o f VZV-specific memory cells and the risk of 
VZV recurrence, the absence of detectable responses for prolonged periods appears 
to be a necessary but not a sufficient condition for VZV reactivation from latency.
This obseiwation suggests that non-specific antiviral immunity helps to restrict the 
symptoms o f VZV reactivation.
(. . .  and perhaps not just “the symptoms?”) In the absence o f a satisfactory animal model o f 
reactivation, the type of explantation experiments carried out in [3] may provide a good platform 
for falsifying the above model. This could be done by incubating explanted tissue with IFN - 7
or IL 1 2 .
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6.1 Final comments
It is clear that the work o f characterising latency is still in its infancy; only the presence o f about 
13% o f VZV genes has been probed in published literature. Work in progress using microarray 
techniques [56] seeks to remedy this defect in order to obtain a fuller picture o f VZV and 
host genome activity during latency. Clearly, once such information is available, the focus 
will switch to characterising protein-protein interactions between different VZV gene products, 
between VZV gene products and host cell proteins, and, something that has been neglected so 
far, direct RNA-protein interactions. All this will surely aid in achieving the theiapeutic goals 
described in the Introduction. Furthermore, at this stage the search is still on for an unequivocal 
hallmark o f latency. Expression o f VZV gene 63 is considered a good indication of latency, yet 
our results in [3] indicated that gene 63 activity is not unique to it. More studies on explanted 
tissue on the pattern o f [3 ] are needed to differentiate fully between latency and post- excision 
reactivation. The following quote from [29] can not be improved upon; “Our results highlight 
the dearth of larowledge concerning VZV gene expression during latent infection.
There is also a dearth of understanding o f the nature o f coimnunication between the latent vims 
and its host cell, and by implication, with the organism as a whole. These communication pro­
cesses, surely, are the key to understanding and thus controlling o f the processes o f reactivation 
of the latent virus: the virus has a way o f gauging the host’s immunocompetence vis à vis itself 
and reactivates when the host is deemed sufficiently immunocompromised. O f course this does 
not rule out the possibility o f continual sub-clinical reactivation. Thus an interesting venue of 
research would focus on host cells themselves and establish their ways o f communicating, via 
receptors for ILs and TNFa, with the body’s immune system. Once these receptors are well 
characterised, one should investigate the interaction o f viral proteins, such as IE62, and oth­
ers yet to be discovered, with these receptors and other constituents of the signal transduction 
pathway.
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6.2 Suggestions for future research
6.2.1 Latency establishment inhibition
As discussed in Chapter 3, there are two ways for the vims to reach sensory ganglia, either by 
retrograde transport from skin lesions, or by the haematogenic route, from e.g. infected T cells. 
Establishing the relative importance o f these two mechanisms should be a priority. ORF47 
mutants which do not seem to infect T cells [80] are an obvious candidate for such a study 
in an animal model. Another possibility is to compare the abundance o f latent VZV genomes 
in DRGs and in ganglia which do not innervate the skin, both coming from the same source; 
preferential infection o f DRGs will indicate that the retrograde transport route is operational. 
O f course the fact that zoster is the preferential way o f latent vim s reactivation already indicates 
that this route is important. If  the retrograde transport mechanism is an important way of vims 
delivery to sensory ganglia, an obvious strategy o f controlling the establishment of latency 
seems to present itself. It makes sense to assume that the initiation o f the axonal transport uses 
the same mechanism as virion absorption to a target cell in a productive lytic cycle. Thus it is 
not clear that local administration o f heparin to skin lesions would not inhibit (simply by kinetic 
effects) the penetration o f the vims into neurons. Additionally, a closer study o f major fusogens 
such as gH will reveal the structure of their active sites and the nature o f the cell-type specific 
receptors they bind to. Hence once neuron-specific glycoprotein is identified and characterised, 
administering the ligand it binds to to skin lesions will perforce lower the probability of latency 
establishment.
6.2.2 Microarray analysis of VZV transcription
Using a chip containing 75bp oligomers to each VZV ORF will enable the study of variations in 
the entire transcriptome to variations in host cell type, vims strain and the analysis of different 
clinical samples and their relation to disease phenotype. In addition host microarrays can be 
used to determine differences in cellular gene regulation on infection with VZV. These studies
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may provide background information for experiments to link these various response pheno­
types with mechanisms of VZV pathogenesis that are important for the natural course of human 
infection [52].
6.2.3 Novel vaccination procedures
Many complications o f zoster seem to involve a common mechanism: on reactivation, the virus 
is disseminated by infected T cells and it is its seeding (in arteries, brain, etc.) that causes the 
pathology. Once it is conclusively shown what gene product is responsible for T cell tropism 
(e.g. the ORF47 protein as suggested in [10]), it makes sense, on first manifestation with zoster, 
to use passive vaccination with anti ORF47 protein antibodies to decrease the probability of T 
cell vims transport to target organs. Alternatively, immunisation with polyvalent antibodies to 
several latency associated proteins could be administered to those most at risk.
6.2.4 RNA silencing
An emerging technology that can have implications for latency research is the use o f small 
interfering RNAs (siRNAs) [45, 6 8 , 98]. These are small molecules o f double stranded RNA 
with overhangs, which have the property that in many systems they initiate the degradation 
of RNA molecule they bind to. In theory it is possible to direct siRNA against mRNA o f 
any gene and thus cause its timed and time-dependent inhibition; see [6 8 ] for references of 
such work on the respiratory syntycial vims. There are many practical problems related to the 
delivery o f siRNA to target organs; [6 8 ] also contains reports o f siRNA delivery in the mouse. 
If the technical problems were to be resolved, a possible procedure to deliver siRNA directed 
against mRNA of the IE genes coding for proteins expressed in latency at different times after 
inoculation (for example, in the Liège rat system) in order to see expression of which viral 
genes is necessary for latency establishment and maintenance. This is in theory a very flexible 
teclmique which allows using combinations of siRNAs directed against different niRNAs and a
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complete freedom in scheduling delivery.
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